ArticleOpen life sciences2025
Longitudinal monitoring of autoantibody dynamics in patients with early-stage non-small-cell lung cancer undergoing surgery.
Article in Open life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is one of the most common and deadly malignancies worldwide, underscoring the need for reliable biomarkers that can inform prognosis and guide postoperative surveillance. This prospective study examined longitudinal changes in 10 tumor-associated autoantibodies in 71 patients with early-stage non-small-cell lung cancer (NSCLC) who underwent surgical resection. Blood samples were collected preoperatively and at 3-, 6-, and 12-month post-surgery. Enzyme-linked immunosorbent assays were used to measure serum autoantibodies against p53, MUC1, NY-ESO-1, APE1, PGP9.5, SOX2, GBU4-5, GAGE7, CAGE, and MAGE1. Logistic regression models assessed associations with 1-year recurrence, while Cox proportional hazards models evaluated overall survival. Substantial reductions in p53, GBU4-5, and CAGE autoantibodies correlated with lower recurrence risk and improved 1-year survival, even after false discovery rate adjustment (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.